Thanks to in-utero blood transfusion technology, what was once a fatal diagnosis in the womb can now result in live births.

Exagamglogene autotemcel (exa-cel), a CRISPR/Cas9 gene-edited cell therapy, eliminated vaso-occlusive crises in 97% of ...

Jesse Gelsinger died after receiving a gene therapy treatment to treat a liver disease. The death sparked an investigation ...

The first child to receive a new experimental gene therapy for a rare neurological disorder died a few days after dosing, the ...

A new analyst survey suggests that doctors are still prescribing Sarepta’s Elevidys, even after a series of deaths in certain ...

Prominent critics say Sarepta’s Elevidys Duchenne therapy may overstate how much gene it delivers—raising new questions about ...

Fresh treatments for rare skin diseases shift the focus from symptom management to repair and help children with such ...

At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

Ocugen (NasdaqCM:OCGN) just gave investors something to talk about by announcing a new licensing agreement that hands Kwangdong Pharmaceutical the exclusive rights to commercialize its gene therapy ...

Capsida is investigating the root cause of the death, which occurred in the first patient treated in a trial of the company’s ...

The medium, which is designed for high density perfusion culture, is available in a variety of media package options for continuous processing.